Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

Therapeutic targeting of cell transition: ready for clinical prime-time?

Targeting immune cell recruitment in atherosclerosis

Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential

Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment

Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis

The fibrous cap: a promising target in the pharmacotherapy of atherosclerosis

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Targeting cardiovascular inflammation: next steps in clinical translation

A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Moving from lipids to leukocytes: inflammation and immune cells in atherosclerosis

Targeting Epigenetics and Non-Coding RNAs in Atherosclerosis: from Mechanisms to Therapeutics.

Atherosclerosis: cellular mechanisms

Abstract 157: Atherosclerosis Is A Smooth Muscle Cell-driven Tumor-like Disease

Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease

Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities

Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming

Therapeutic targeting of chemokine interactions in atherosclerosis

Lipid-laden Foam Cells in the Pathology of Atherosclerosis: Shedding Light on New Therapeutic Targets

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease